(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Nov. 11, 2026 (GLOBE NEWSWIRE) -- "Antisense and RNAi Therapeutics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global antisense and RNAi therapeutics market was valued at US$1.5 billion in 2025 and is projected to reach US$2.6 billion by 2032, advancing at a compound annual growth rate of 7.7%. Market expansion is being supported by progress in genomics, increasing regulatory approvals for RNA-based medicines, continued innovation in oligonucleotide delivery and growing demand for targeted treatments across rare, genetic and chronic diseases.
Antisense and RNAi Therapeutics Reshape Targeted Medicine
Antisense oligonucleotides and RNA interference therapeutics enable highly specific regulation of disease-associated gene expression. By targeting messenger RNA, these platforms can suppress harmful protein production, modify RNA splicing and address molecular mechanisms that may not respond effectively to conventional small-molecule or biologic therapies.
Commercial and clinical successes have strengthened confidence in RNA-based drug development. Nusinersen, marketed as Spinraza, has demonstrated the therapeutic potential of splice-modifying antisense technology in spinal muscular atrophy. Patisiran, marketed as Onpattro, has validated RNA interference as a treatment strategy for hereditary transthyretin-mediated amyloidosis. Inclisiran has further expanded the field into cardiovascular care by targeting PCSK9 to support sustained cholesterol reduction.
The market is moving beyond its initial concentration on rare genetic disorders. Development pipelines increasingly include candidates for cancer, cardiovascular disease, metabolic disorders, viral infections and neurodegenerative conditions. This widening therapeutic scope is creating new opportunities for pharmaceutical companies, biotechnology developers, delivery-platform specialists and investors.
Delivery and Chemistry Innovations Support Market Growth
Oligonucleotide stability, tissue-specific delivery, cellular uptake and immune activation remain central development considerations. Chemical modifications, including phosphorothioate backbones and locked nucleic acids, are improving molecular stability, binding performance and pharmacokinetic characteristics. Lipid nanoparticles and ligand-conjugation strategies are also enhancing tissue targeting and intracellular delivery, particularly for liver-directed therapies.
Advances involving small interfering RNA, microRNA and next-generation delivery systems are extending the potential reach of RNA therapeutics. Continued improvements in selectivity, durability, tolerability and manufacturing scalability are expected to strengthen commercial viability and support development for diseases previously considered difficult to treat.
Key Antisense and RNAi Therapeutics Market Drivers
Rapid advances in genomics, sequencing and disease-target identification. Increasing approvals and clinical validation of antisense and RNAi medicines. Expansion from rare diseases into oncology, cardiovascular, metabolic and neurological applications. Improved oligonucleotide chemistry, stability and tissue-specific delivery. Growing pharmaceutical investment in RNA-based drug pipelines and platform technologies. Rising demand for precision medicines targeting underlying disease mechanisms. Greater regulatory familiarity with RNA-based therapeutic development and evaluation.
Market Segment and Regional Outlook
The report analyzes the global antisense and RNAi therapeutics market by technology, route of administration and geography. Technology segments include antisense RNA and RNA interference. Routes of administration include pulmonary delivery, intravenous injection, intradermal injection, intraperitoneal injection, topical delivery and other administration routes.
The antisense RNA segment is forecast to reach US$1.3 billion by 2032, expanding at a CAGR of 7.5%. The RNA interference segment is projected to grow at a CAGR of 7.9% over the analysis period.
The United States market was valued at US$415.9 million in 2025. China is forecast to expand at an 11.6% CAGR and reach US$554 million by 2032, reflecting strong potential for biotechnology investment, clinical development and adoption of advanced therapeutics. The report also examines trends in Canada, Japan, Germany and other major markets across Europe, Asia-Pacific, Latin America, the Middle East and Africa.
Report Scope and Business Value
The analysis provides independent annual sales estimates and market forecasts from 2025 through 2032. It evaluates market dynamics, growth opportunities, restraints, competitive positioning and regional developments. Coverage is designed to help organizations assess emerging revenue opportunities, prioritize geographic markets, monitor therapeutic pipelines and support strategic investment decisions.
Key questions addressed include:
How will the global antisense and RNAi therapeutics market evolve through 2032? Which technologies and administration routes offer the strongest growth prospects? What scientific, commercial and regulatory factors are influencing market expansion? How are competitive conditions changing across major geographic regions? Which companies are shaping the development and commercialization landscape?
Competitive Landscape
The report examines companies participating in antisense technology, RNA interference, oligonucleotide chemistry and therapeutic delivery. Featured organizations include Acuitas Therapeutics, Alnylam Pharmaceuticals, Antisense Therapeutics, Arbutus Biopharma, Benitec Biopharma, Bio-Path Holdings, GlaxoSmithKline, Ionis Pharmaceuticals, Olix Pharmaceuticals, Regulus Therapeutics, Sanofi, Sarepta Therapeutics, Silence Therapeutics and Sirnaomics, among others.
Company coverage provides insight into market presence, development activity, competitive strategy and geographic participation. Complimentary updates for one year support continued monitoring of relevant market and industry developments.
Domain Expert Insights and Differentiated Intelligence
The report incorporates perspectives from experts across industry, enterprise and academia, adding strategic context beyond conventional published research. The report tracks emerging shifts through expert discussions, corporate activity, conference sessions, keynote presentations, panel discussions, company disclosures, annual reports, institutional publications and other validated intelligence sources.
These signals are synthesized to identify the direction of the antisense and RNAi therapeutics market, the forces driving change and the developments most likely to influence strategy. Competitive analysis extends beyond a single global market-share estimate by examining regional structures where market conditions, participants and adoption patterns differ materially. This approach provides a more relevant assessment of the companies and technologies shaping the global competitive environment.
Key Attributes
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment